HUE047037T2 - JAK1 inhibitor 4-(3-pirazolilamino)-benzimidazol származék rák kezelésére - Google Patents

JAK1 inhibitor 4-(3-pirazolilamino)-benzimidazol származék rák kezelésére

Info

Publication number
HUE047037T2
HUE047037T2 HUE16750326A HUE16750326A HUE047037T2 HU E047037 T2 HUE047037 T2 HU E047037T2 HU E16750326 A HUE16750326 A HU E16750326A HU E16750326 A HUE16750326 A HU E16750326A HU E047037 T2 HUE047037 T2 HU E047037T2
Authority
HU
Hungary
Prior art keywords
pyrazolylamino
treating cancer
benzimidazole derivative
jak1 inhibitor
jak1
Prior art date
Application number
HUE16750326A
Other languages
English (en)
Inventor
Joshua Ryan Clayton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE047037T2 publication Critical patent/HUE047037T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE16750326A 2015-08-04 2016-07-28 JAK1 inhibitor 4-(3-pirazolilamino)-benzimidazol származék rák kezelésére HUE047037T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562200684P 2015-08-04 2015-08-04

Publications (1)

Publication Number Publication Date
HUE047037T2 true HUE047037T2 (hu) 2020-04-28

Family

ID=56618268

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16750326A HUE047037T2 (hu) 2015-08-04 2016-07-28 JAK1 inhibitor 4-(3-pirazolilamino)-benzimidazol származék rák kezelésére

Country Status (27)

Country Link
US (1) US9556153B1 (hu)
EP (1) EP3331873B1 (hu)
JP (1) JP6470869B2 (hu)
KR (1) KR102032792B1 (hu)
CN (1) CN108026076B (hu)
AR (1) AR105400A1 (hu)
AU (1) AU2016302748B2 (hu)
BR (1) BR112017028240B1 (hu)
CA (1) CA2990471C (hu)
CY (1) CY1121909T1 (hu)
DK (1) DK3331873T3 (hu)
EA (1) EA033572B1 (hu)
ES (1) ES2743499T3 (hu)
HR (1) HRP20191227T1 (hu)
HU (1) HUE047037T2 (hu)
LT (1) LT3331873T (hu)
MA (1) MA44383B1 (hu)
MD (1) MD3331873T2 (hu)
ME (1) ME03451B (hu)
MX (1) MX2018001306A (hu)
NZ (1) NZ738247A (hu)
PL (1) PL3331873T3 (hu)
PT (1) PT3331873T (hu)
RS (1) RS58974B1 (hu)
SI (1) SI3331873T1 (hu)
TW (1) TW201718555A (hu)
WO (1) WO2017023672A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ748942A (en) 2016-07-14 2020-08-28 Lilly Co Eli Pyrazolylaminobenzimidazole derivatives as jak inhibitors
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
KR20150008907A (ko) * 2012-06-14 2015-01-23 일라이 릴리 앤드 캄파니 Jak1 및 jak2의 억제제
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
BR112017028240A2 (pt) 2018-09-04
EA201792676A1 (ru) 2018-07-31
TW201718555A (zh) 2017-06-01
CN108026076B (zh) 2020-07-10
US20170037034A1 (en) 2017-02-09
AR105400A1 (es) 2017-09-27
JP6470869B2 (ja) 2019-02-13
AU2016302748B2 (en) 2019-02-28
JP2018524384A (ja) 2018-08-30
MA44383B1 (fr) 2019-08-30
AU2016302748A1 (en) 2018-01-04
DK3331873T3 (da) 2019-08-12
US9556153B1 (en) 2017-01-31
SI3331873T1 (sl) 2019-08-30
KR20180022966A (ko) 2018-03-06
KR102032792B1 (ko) 2019-10-16
RS58974B1 (sr) 2019-08-30
CA2990471A1 (en) 2017-02-09
ME03451B (me) 2020-01-20
PT3331873T (pt) 2019-09-12
ES2743499T3 (es) 2020-02-19
LT3331873T (lt) 2019-08-26
CA2990471C (en) 2020-01-07
EA033572B1 (ru) 2019-11-06
CY1121909T1 (el) 2020-10-14
WO2017023672A1 (en) 2017-02-09
MX2018001306A (es) 2018-05-17
EP3331873A1 (en) 2018-06-13
EP3331873B1 (en) 2019-06-26
NZ738247A (en) 2019-06-28
BR112017028240B1 (pt) 2023-04-11
MA44383A (fr) 2019-01-23
PL3331873T3 (pl) 2019-11-29
CN108026076A (zh) 2018-05-11
HRP20191227T1 (hr) 2019-10-18
MD3331873T2 (ro) 2019-11-30

Similar Documents

Publication Publication Date Title
IL262237B (en) Macrocyclic mcl1 inhibitors for cancer therapy
IL287517A (en) Benzimidazole compounds as c-kit inhibitors
RS63359B1 (sr) Heterociklična jedinjenja kao inhibitori pi3k-gama
HRP20200133T1 (hr) Novi supstituirani derivati cijanoindolina kao inhibitori nik
IL255750A (en) Heterocyclic compounds as kinase inhibitors
IL278247B (en) mct4 inhibitors to treat the disease
ZA201607570B (en) Metalloenzyme inhibitor compounds as fungicides
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
GB201403536D0 (en) Inhibitor compounds
GB201513481D0 (en) Inhibitor compounds
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
GB201505658D0 (en) Inhibitor compounds
IL248354A0 (en) Metalloenzyme inhibitor compounds as fungicides
HK1257565A1 (zh) 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
EP3526216C0 (en) BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS
ME03451B (me) Derivat 4-(3-pirazolilamino)benzimidazola kao inhibitor jak1, namijenjen liječenju raka
EP3303335A4 (en) HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF PSORIASIS
HK1259615A1 (zh) 谷氨酸-高z元素化合物治療癌症
GB201621619D0 (en) Inhibitor compounds
GB201522453D0 (en) Inhibitor compounds
GB201500644D0 (en) Inhibitor compounds